Marina Djurovic1, Alberto M Pereira2, Johannes W A Smit3, Olga Vasovic4, Svetozar Damjanovic5, Zvezdana Jemuovic5, Dragan Pavlovic6, Dragana Miljic5, Sandra Pekic5, Marko Stojanovic5, Milika Asanin7, Gordana Krljanac7, Milan Petakov5. 1. Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia. prof.marina.djurovic@gmail.com. 2. Department of Endocrinology and Metabolic Diseases, and Centre for Endocrine Tumors Leiden, Leiden University Medical Centre, Leiden, The Netherlands. 3. Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre, Nijmegen, The Netherlands. 4. Institute for Gerontology and Palliative Care, Belgrade, Belgrade, Serbia. 5. Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia. 6. Institute of Neurology, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia. 7. Clinic for Cardiology, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia.
Abstract
OBJECTIVE: Intrinsic imperfections of thyroid hormone replacement therapy may affect long-term general well-being. In patients with Hashimoto thyroiditis (HT), cognitive functioning may be affected via altered thyroid hormones action as well as by the autoimmune process. The aim of this study was to evaluate cognitive function and quality of life (QoL) in patients on long-term levothyroxine replacement for HT in relation to thyroid function tests and TPO (thyroid-peroxidase) antibody (TPOAb) status. DESIGN: Retrospective cross-sectional study. PATIENTS AND MEASUREMENTS: One-hundred-and thirty patients with HT on long-term levothyroxine replacement and 111 euthyroid control subjects. Both groups were divided into two age subgroups, 20-49 years (N = 59 vs N = 79) and > 50 years (N = 71 vs N = 32). Evaluation included biochemical and neuropsychological tests, evaluating attention, global cognitive status, verbal and working memory, executive function, depression and anxiety, and quality of life. We used ANOVA and partial correlations to test for significant associations. RESULTS: FT4 (free-thyroxine), FT3 (free-triiodothyronine) levels and FT3/FT4 ratio were not different between patients and controls. Mean TSH (thyroid-stimulating hormone) was normal in all subjects but significantly higher in the patients (20-49 yrs:3.64 ± 2.74 vs 1.93 ± 1.10, >50 yrs:3.93 ± 2.84 vs 1.91 ± 0.90). Antibodies (TgAb,TPOAb) were higher in patients. Global cognitive function (MMSE-Mini mental state examination), conceptual tracking (TMT-Trail Making Test:A/B), verbal divergent thinking (like Phonemic fluency test), and anxiety and depression scores were significantly worse in patients vs controls. QoL was impaired in patients. there was a significant negative correlation between antibodies (TPOAb, TgAb) and quality in life (total SF36 score). CONCLUSION: Patients on long-term levothyroxine replacement show persistent impairments in both cognitive functioning and general well-being.
OBJECTIVE: Intrinsic imperfections of thyroid hormone replacement therapy may affect long-term general well-being. In patients with Hashimoto thyroiditis (HT), cognitive functioning may be affected via altered thyroid hormones action as well as by the autoimmune process. The aim of this study was to evaluate cognitive function and quality of life (QoL) in patients on long-term levothyroxine replacement for HT in relation to thyroid function tests and TPO (thyroid-peroxidase) antibody (TPOAb) status. DESIGN: Retrospective cross-sectional study. PATIENTS AND MEASUREMENTS: One-hundred-and thirty patients with HT on long-term levothyroxine replacement and 111 euthyroid control subjects. Both groups were divided into two age subgroups, 20-49 years (N = 59 vs N = 79) and > 50 years (N = 71 vs N = 32). Evaluation included biochemical and neuropsychological tests, evaluating attention, global cognitive status, verbal and working memory, executive function, depression and anxiety, and quality of life. We used ANOVA and partial correlations to test for significant associations. RESULTS: FT4 (free-thyroxine), FT3 (free-triiodothyronine) levels and FT3/FT4 ratio were not different between patients and controls. Mean TSH (thyroid-stimulating hormone) was normal in all subjects but significantly higher in the patients (20-49 yrs:3.64 ± 2.74 vs 1.93 ± 1.10, >50 yrs:3.93 ± 2.84 vs 1.91 ± 0.90). Antibodies (TgAb,TPOAb) were higher in patients. Global cognitive function (MMSE-Mini mental state examination), conceptual tracking (TMT-Trail Making Test:A/B), verbal divergent thinking (like Phonemic fluency test), and anxiety and depression scores were significantly worse in patients vs controls. QoL was impaired in patients. there was a significant negative correlation between antibodies (TPOAb, TgAb) and quality in life (total SF36 score). CONCLUSION:Patients on long-term levothyroxine replacement show persistent impairments in both cognitive functioning and general well-being.
Entities:
Keywords:
Anti-TPO; Cognitive function; Hypothyroidism; L-thyroxine; Long-term replacement; Quality of life
Authors: J Parle; L Roberts; S Wilson; H Pattison; A Roalfe; M S Haque; C Heath; M Sheppard; J Franklyn; F D R Hobbs Journal: J Clin Endocrinol Metab Date: 2010-05-25 Impact factor: 5.958
Authors: David J Stott; Nicolas Rodondi; Patricia M Kearney; Ian Ford; Rudi G J Westendorp; Simon P Mooijaart; Naveed Sattar; Carole E Aubert; Drahomir Aujesky; Douglas C Bauer; Christine Baumgartner; Manuel R Blum; John P Browne; Stephen Byrne; Tinh-Hai Collet; Olaf M Dekkers; Wendy P J den Elzen; Robert S Du Puy; Graham Ellis; Martin Feller; Carmen Floriani; Kirsty Hendry; Caroline Hurley; J Wouter Jukema; Sharon Kean; Maria Kelly; Danielle Krebs; Peter Langhorne; Gemma McCarthy; Vera McCarthy; Alex McConnachie; Mairi McDade; Martina Messow; Annemarie O'Flynn; David O'Riordan; Rosalinde K E Poortvliet; Terence J Quinn; Audrey Russell; Carol Sinnott; Jan W A Smit; H Anette Van Dorland; Kieran A Walsh; Elaine K Walsh; Torquil Watt; Robbie Wilson; Jacobijn Gussekloo Journal: N Engl J Med Date: 2017-04-03 Impact factor: 91.245
Authors: Héctor F Escobar-Morreale; José I Botella-Carretero; Francisco Escobar del Rey; Gabriella Morreale de Escobar Journal: J Clin Endocrinol Metab Date: 2005-05-31 Impact factor: 5.958
Authors: Wendy M van der Deure; Bente C Appelhof; Robin P Peeters; Wilmar M Wiersinga; Ellie M Wekking; Jochanan Huyser; Aart H Schene; Jan G P Tijssen; Witte J G Hoogendijk; Theo J Visser; Eric Fliers Journal: Clin Endocrinol (Oxf) Date: 2008-04-10 Impact factor: 3.478
Authors: Ajay K Parsaik; Balwinder Singh; Rosebud O Roberts; Shane Pankratz; Kelly K Edwards; Yonas E Geda; Hossein Gharib; Bradley F Boeve; David S Knopman; Ronald C Petersen Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302
Authors: Matthew D Ettleson; Ava Raine; Alice Batistuzzo; Samuel P Batista; Elizabeth McAninch; Maria Cristina T V Teixeira; Jacqueline Jonklaas; Neda Laiteerapong; Miriam O Ribeiro; Antonio C Bianco Journal: Endocr Pract Date: 2021-12-08 Impact factor: 3.701
Authors: Benjamín Romero-Gómez; Paula Guerrero-Alonso; Juan Manuel Carmona-Torres; Blanca Notario-Pacheco; Ana Isabel Cobo-Cuenca Journal: Int J Environ Res Public Health Date: 2019-11-28 Impact factor: 3.390